The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Tirzepatide , a dual GIP/GLP-1 receptor activator , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor https://explorebookmarks.com/story21539714/tirzepatide-and-nad-a-triple-threat-approach-to-physiological-condition